巴曲酶在大血管动脉粥样硬化性脑梗死患者中的应用效果  

Application value of Batroxobin in the treatment of patients with atherosclerotic cerebral infarction of macrovascular

作　　者：熊学忠 谭亚玲 管小君 XIONG Xuezhong;TAN Yaling;GUAN Xiaojun(Department of Internal Medicine,the Second People's Hospital of Zhangshu,Jiangxi Province,Zhangshu 331211,China;Department of Neurology,the Second People's Hospital of Zhangshu,Jiangxi Province,Zhangshu 331211,China;Department of Pharmacy,the Second People's Hospital of Zhangshu,Jiangxi Province,Zhangshu 331211,China)

机构地区：[1]江西省樟树市第二人民医院大内科,江西樟树331211 [2]江西省樟树市第二人民医院神经内科,江西樟树331211 [3]江西省樟树市第二人民医院药剂科,江西樟树331211

出　　处：《中国当代医药》2025年第7期46-50,共5页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(202210947);江西省宜春市医疗卫生指导性科技计划项目(JXYC2024KSA248)。

摘　　要：目的探究巴曲酶在大血管动脉粥样硬化性脑梗死患者中的应用效果。方法选取2022年7月至2023年11月期间樟树市第二人民医院的80例大血管动脉粥样硬化性脑梗死患者作为研究对象,根据随机数字表法分为对照组(n=40)和观察组(n=40)。对照组进行常规动脉粥样硬化性脑梗死治疗,观察组则在对照组的基础上加用巴曲酶。比较两组临床总有效率、进展性脑梗死发生率、不良反应总发生率、治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分、大脑中动脉(MCA)、大脑后动脉(PCA)、大脑前动脉(ACA)的平均血流速(Vm)和搏动指数(PI)、血小板α颗粒膜蛋白-140(GMP-140)、血管性血友病因子(vWF)及纤维蛋白原(FIB)。结果观察组的临床总有效率高于对照组,进展性脑梗死发生率低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);治疗7、15 d观察组的NIHSS评分、MCA、PCA、ACA的PI及血栓前状态分子低于对照组,MCA、PCA、ACA的Vm高于对照组,差异有统计学意义(P<0.05)。结论巴曲酶防治大血管动脉粥样硬化性脑梗死发展为进展性脑梗死的临床效果较好,安全性值得肯定,对于脑血流及血栓前状态分子的改善作用较好,因此在本类患者中的应用价值较高。Objective To investigate the clinical application effect of Batroxobin in the treatment of patients with atherosclerotic cerebral infarction of macrovascular.Methods Eighty patients with atherosclerotic cerebral infarction of macrovascular in the Second People's Hospital of Zhangshu from July 2022 to November 2023 were divided into control group(40 cases)and observation group(40 cases)by the random number table method.The control group were treated with treatment for atherosclerotic cerebral infarction of macrovascular,the observation group were treated with Batroxobin.The total effective rates,progressive cerebral infarction rates,adverse reaction rates,National Institute of Health stroke scale(NIHSS)score,mean blood flow velocity(Vm),pulsation index(PI)of middle cerebral artery(MCA),posterior cerebral artery(PCA)and anterior cerebral artery(ACA),granule membrane protein-140(GMP-140),von willebrand factor(vWF)and fibrinogen(FIB)before and after the treatment of two groups were compared.Results The total effective rate of observation group was higher than that of control group,the progressive cerebral infarction rate was lower than that of control group,the differences were statistically significant(P<0.05),the adverse reaction rates of two groups were compared,the differences were not statistically significant(P>0.05),the NIHSS score,PI of MCA,PCA and ACA and prethrombotic state indexes of observation group at 7th and 15th day after the treatment were lower than those of control group,the Vm of MCA,PCA and ACA were higher than those of control group,the differences were statistically significant(P<0.05).Conclusion The clinical effect of Batroxobin in the prevention and treatment of progressive cerebral infarction caused by atherosclerotic cerebral infarction of macrovascular is better,its safety is worthy of affirm,and its improvement effect for cerebral blood flow and rethrombotic state indexes is better too,so its application value in these patients is higher.

关 键 词：巴曲酶 大血管动脉粥样硬化性脑梗死 进展性脑梗死 脑血流 血栓前状态分子 

分 类 号：R741[医药卫生—神经病学与精神病学]